Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
asciminib - BCR-ABL inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04971226 ASC4FIRST (CABL001J12301)
Chronic myeloid leukemia, 1st line
Phase 3
402
Major Molecular Response (MMR) at week 48
Arm 1: asciminib 80 mg QD
Arm 2: Investigator selected TKI including one of the below treatments:
-Imatinib 400 mg QD
- Nilotinib 300 mg BID
- Dasatinib 100 mg QD
- Bosutinib 400 mg QD
Patients with newly diagnosed philadelphia chromosome positive chronic
myelogenous leukemia in chronic phase
Target Patients
Read-out Milestone(s)
2024
Publication
TBD
134 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation